Rachel Schiff

Summary

Affiliation: Texas Medical Center
Country: USA

Publications

  1. ncbi request reprint Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance
    Rachel Schiff
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 10:331S-6S. 2004
  2. ncbi request reprint Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
    M Carolina Gutierrez
    Breast Center and Department of Pathology, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 23:2469-76. 2005
  3. pmc Mechanisms of endocrine resistance in breast cancer
    C Kent Osborne
    Dan L Duncan Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Annu Rev Med 62:233-47. 2011
  4. pmc Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype
    Changhua Zhou
    Department of Chemistry, Xavier University of Louisiana, New Orleans, LA 70125, USA
    Breast Cancer Res 10:R105. 2008
  5. ncbi request reprint Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators
    Rachel Schiff
    Department of Medicine, Baylor College of Medicine, Breast Center room N1230, One Baylor Plaza MS 600, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 56:10-20. 2005
  6. ncbi request reprint Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response
    Rachel Schiff
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 9:447S-54S. 2003
  7. pmc Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer
    Rachel Schiff
    Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
    Breast Cancer Res 7:205-11. 2005
  8. pmc Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs)
    Rachel Schiff
    The Breast Center, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Breast Cancer Res 5:228-31. 2003
  9. ncbi request reprint Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy
    Grazia Arpino
    Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    J Natl Cancer Inst 99:694-705. 2007
  10. pmc Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts
    Chad J Creighton
    The Dan L Duncan Cancer Center, Baylor College of Medicine, Room N1230 02, One Baylor Plaza BCM 600, Houston, TX 77030, USA
    Cancer Res 68:7493-501. 2008

Collaborators

Detail Information

Publications65

  1. ncbi request reprint Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance
    Rachel Schiff
    Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
    Clin Cancer Res 10:331S-6S. 2004
    ..We will also emphasize open questions and future challenges in the dynamic research field of molecular ER biology from the endocrine therapy perspective...
  2. ncbi request reprint Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase
    M Carolina Gutierrez
    Breast Center and Department of Pathology, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 23:2469-76. 2005
    ..To evaluate growth factor receptor cross talk with the estrogen receptor (ER) in paired clinical breast cancer specimens and in a xenograft model before tamoxifen and at tumor progression as a possible mechanism for tamoxifen resistance...
  3. pmc Mechanisms of endocrine resistance in breast cancer
    C Kent Osborne
    Dan L Duncan Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Annu Rev Med 62:233-47. 2011
    ..Results of recent clinical studies, while partly supporting this approach, also highlight the need to better identify a priori the patients whose tumors are most likely to benefit from these specific cotargeting strategies...
  4. pmc Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype
    Changhua Zhou
    Department of Chemistry, Xavier University of Louisiana, New Orleans, LA 70125, USA
    Breast Cancer Res 10:R105. 2008
    ....
  5. ncbi request reprint Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators
    Rachel Schiff
    Department of Medicine, Baylor College of Medicine, Breast Center room N1230, One Baylor Plaza MS 600, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 56:10-20. 2005
    ....
  6. ncbi request reprint Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response
    Rachel Schiff
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 9:447S-54S. 2003
    ..Thus, the interactions of these diverse elements are essential considerations in defining new predictive and therapeutic tools...
  7. pmc Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer
    Rachel Schiff
    Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas, USA
    Breast Cancer Res 7:205-11. 2005
    ..Preclinical data suggest that blockade of selected growth factor receptor signaling can overcome this type of resistance, and this strategy is already being tested in clinical trials...
  8. pmc Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs)
    Rachel Schiff
    The Breast Center, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Breast Cancer Res 5:228-31. 2003
    ..Two recent studies in preclinical model systems that evaluate mechanisms of action of these new drugs and suggestions about their optimal clinical use are discussed...
  9. ncbi request reprint Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy
    Grazia Arpino
    Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    J Natl Cancer Inst 99:694-705. 2007
    ..We investigated whether blockade of all HER homo- and heterodimer pairs by combined treatment with several inhibitors could more effectively inhibit tumor growth in such models...
  10. pmc Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts
    Chad J Creighton
    The Dan L Duncan Cancer Center, Baylor College of Medicine, Room N1230 02, One Baylor Plaza BCM 600, Houston, TX 77030, USA
    Cancer Res 68:7493-501. 2008
    ..Over time, the molecular phenotype of breast cancer can change...
  11. pmc Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies
    Albert C Chen
    Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
    Breast Cancer Res Treat 134:583-93. 2012
    ..These mucin-rich tumors reactivate the HER2 pathway and shift their molecular phenotype to become more ER-negative/HER2-positive...
  12. ncbi request reprint Estrogen-mediated down-regulation of E-cadherin in breast cancer cells
    Steffi Oesterreich
    The Breast Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Res 63:5203-8. 2003
    ..We propose that estrogen-mediated down-regulation of E-cadherin is a novel way of reducing E-cadherin levels in estrogen receptor-positive breast cancer...
  13. ncbi request reprint Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
    Jiang Shou
    The Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 96:926-35. 2004
    ..We used a breast cancer model system with high expression of AIB1 and HER2 to investigate the possible mechanisms underlying this resistance...
  14. ncbi request reprint Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance
    Grazia Arpino
    Breast Center, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA
    J Natl Cancer Inst 97:1254-61. 2005
    ..We hypothesized that ER+/PR- breast tumors are more likely than ER+/PR+ breast tumors to have an aggressive phenotype, to express HER-1 and overexpress HER-2, and are less likely to benefit from tamoxifen adjuvant therapy...
  15. ncbi request reprint Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy
    Xiaojiang Cui
    Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Oncol 23:7721-35. 2005
    ..Finally, we will consider the clinical implications of these observations...
  16. pmc Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts
    Mothaffar F Rimawi
    Lester and Sue Smith Breast Center, Margaret M and Albert B Alkek Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 17:1351-61. 2011
    ....
  17. ncbi request reprint Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer
    C Kent Osborne
    Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    J Natl Cancer Inst 95:353-61. 2003
    ....
  18. pmc β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
    Catherine Huang
    Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77054, USA
    Breast Cancer Res 13:R84. 2011
    ..The β1 integrin resides on the membrane of the breast cancer cell, activating several elements of breast tumor progression including proliferation and survival...
  19. pmc Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
    Chad J Creighton
    Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Breast Cancer Res 12:R40. 2010
    ..We thus examined whether deregulated PI3K signaling in luminal ER+ breast tumors is associated with ER level and activity and intrinsic molecular subtype...
  20. ncbi request reprint Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer
    C Kent Osborne
    Breast Center, Baylor College of Medicine and The Methodist Hospital, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
    Breast 12:362-7. 2003
    ..In turn, ER located in the cell membrane can activate the growth factor receptor pathways. Breast tumors with high levels of AIB1 and HER-2 may be resistant to tamoxifen because of an increase in its estrogen agonist activity...
  21. pmc Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance
    Grazia Arpino
    Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Endocr Rev 29:217-33. 2008
    ....
  22. pmc Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006
    Mothaffar F Rimawi
    Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    J Clin Oncol 31:1726-31. 2013
    ..In this clinical trial, we sought to translate these findings to patients using targeted therapy without chemotherapy...
  23. ncbi request reprint Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations
    Xiaomei Zhang
    Breast Center, Baylor College of Medicine, One Baylor Plaza, N1210 03, Houston, TX 77030, USA
    Oncogene 24:4220-31. 2005
    ..This is a first report of a mouse model of antiestrogen-resistant ER-positive breast cancers, and could provide a powerful tool to study the molecular mechanisms that control antiestrogen resistance...
  24. ncbi request reprint Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor
    Ashby J Morrison
    Department of Molecular and Cellular Biology and The Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Endocrinol 17:1543-54. 2003
    ....
  25. pmc Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers
    Bhuvanesh Dave
    Lester and Sue Smith Breast Center, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 29:166-73. 2011
    ..Understanding of the cellular response to HER2-targeted therapies is needed to tailor treatments and to identify patients less likely to benefit...
  26. ncbi request reprint The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth
    Jana Divisova
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    Breast Cancer Res Treat 98:315-27. 2006
    ..This data supports previous studies indicating a role for GH/IGF in mammary gland development, and suggests that pegvisomant maybe useful for the prevention and/or treatment of estrogen receptor positive breast cancer...
  27. ncbi request reprint Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer
    C Kent Osborne
    Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030 3798, USA
    Clin Cancer Res 11:865s-70s. 2005
    ..This process can be delayed or reversed by simultaneous treatment with growth factor pathway inhibitors. This strategy is now being tested in clinical trials...
  28. ncbi request reprint Neoadjuvant trastuzumab induces apoptosis in primary breast cancers
    Syed K Mohsin
    Breast Center at Baylor College of Medicine The Methodist Hospital, 1 Baylor Plaza, MS 600, Houston, TX 77030, USA
    J Clin Oncol 23:2460-8. 2005
    ..Greater understanding of the cellular response in trastuzumab-treated patients will provide insight into the clinical management of patients...
  29. pmc Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation
    Yen Chao Wang
    Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA
    Breast Cancer Res 13:R121. 2011
    ..Here we investigate resistance mechanisms to each drug alone, or to their combination using a large panel of HER2-positive cell lines made resistant to these drugs...
  30. pmc A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis
    Jessica D Kessler
    Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Science 335:348-53. 2012
    ..Thus, inhibition of SUMOylation may merit investigation as a possible therapy for Myc-driven human cancers...
  31. ncbi request reprint Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters
    Suzanne A W Fuqua
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Res 63:2434-9. 2003
    ..These results suggest that ERbeta expression is not a surrogate for ERalpha in clinical breast tumors and, as such, could be a useful biomarker in its own right...
  32. ncbi request reprint Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer
    Jennifer Parma
    University of Houston College of Pharmacy, Houston, Texas
    Pharmacotherapy 33:1126-9. 2013
    ..To determine if development of acneiform rash is a predictor of objective response rate with lapatinib...
  33. pmc Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study
    C Kent Osborne
    Lester and Sue Smith Breast Center and Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 17:1147-59. 2011
    ..This randomized phase II trial assessed tamoxifen plus placebo or the epidermal growth factor receptor inhibitor gefitinib in estrogen receptor (ER)-positive metastatic breast cancer...
  34. pmc Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes
    Mothaffar F Rimawi
    Department of Medicine, Baylor College of Medicine, Houston, TX, USA
    Cancer 116:1234-42. 2010
    ..We hypothesized that EGFR expression in human breast tumors, when centrally and uniformly assessed, is associated with an aggressive phenotype and resistance to systemic therapy...
  35. ncbi request reprint Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy
    C Kent Osborne
    The Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
    Breast 14:458-65. 2005
    ....
  36. ncbi request reprint Estrogen-receptor biology: continuing progress and therapeutic implications
    C Kent Osborne
    Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600 Houston, TX 77030, USA
    J Clin Oncol 23:1616-22. 2005
  37. ncbi request reprint Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer
    Lakshmi Sampath
    Division of Molecular Imaging, Department of Radiology, Baylor College of Medicine, Houston, TX 77030, USA
    J Nucl Med 48:1501-10. 2007
    ..The stoichiometric ratios "n" and "m" refer to the number of diethylenetriaminepentaacetic acid dianhydride (DTPA) and IRDye 800CW molecules bound per trastuzumab molecule, respectively...
  38. ncbi request reprint Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk
    Suleiman Massarweh
    The Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM 600, Houston, Texas 77030, USA
    Endocr Relat Cancer 13:S15-24. 2006
    ..Ongoing clinical trials of endocrine therapy combined with growth factor pathway inhibitors or their downstream signaling elements promise to further improve the present care for breast cancer patients...
  39. ncbi request reprint Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities
    Suleiman Massarweh
    Department of Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky 40536, USA
    Clin Cancer Res 13:1950-4. 2007
    ....
  40. pmc Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance
    Gladys Morrison
    Lester and Sue Smith Breast Center and Dan L Duncan Cancer Center, Baylor College of Medicine, One Baylor Plaza, BCM 600, Houston, TX, 77030, USA
    Breast Cancer Res Treat 144:263-72. 2014
    ..The absence of tumor regression, however, suggests that additional escape pathways contribute to resistant growth and will need to be targeted to fully circumvent tamoxifen resistance...
  41. pmc A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models
    Xiaomei Zhang
    Lester and Sue Smith Breast Center, Departments of Molecular and Cellular Biology, Pathology, and Molecular and Human Genetics, Baylor College of Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Res 73:4885-97. 2013
    ..These models thus serve as a renewable, quality-controlled tissue resource for preclinical studies investigating treatment response and metastasis...
  42. doi request reprint Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase
    Tingting Sun
    Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Cell 144:703-18. 2011
    ....
  43. pmc Molecular profiles of progesterone receptor loss in human breast tumors
    Chad J Creighton
    Dan L Duncan Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, TX 77030, USA
    Breast Cancer Res Treat 114:287-99. 2009
    ..Patient prognosis and response to endocrine therapy in breast cancer correlate with protein expression of both estrogen receptor (ER) and progesterone receptor (PR), with poorer outcome in patients with ER+/PR- compared to ER+/PR+ tumors...
  44. pmc SGK3 is associated with estrogen receptor expression in breast cancer
    Jun Xu
    Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Breast Cancer Res Treat 134:531-41. 2012
    ..These findings implicate SGK3 as an additional component to a complex and heterogeneous disease, and point to the potential benefits of incorporating SGK3 into the process of breast cancer diagnosis and treatment...
  45. pmc More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response
    Xiaoyong Fu
    Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, BCM600, Houston, TX 77030, USA
    Breast Cancer Res 13:307. 2011
    ..The significance of FOXA1 in the chromatin interactions and transcriptional regulation of both estrogen- and tamoxifen-bound ER, and in supporting tamoxifen-resistant cell growth, may impact current endocrine therapies...
  46. ncbi request reprint Aromatase inhibitors: future directions
    C Kent Osborne
    Breast Center, Baylor College of Medicine and The Methodist Hospital, One Baylor Plaza, BCM 600, Houston, TX 77030, USA
    J Steroid Biochem Mol Biol 95:183-7. 2005
    ....
  47. pmc Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell tumorigenesis
    Yun Kyoung Kang
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Res 68:7887-96. 2008
    ..This is, thus far, the only example of a nuclear receptor coregulator involved in suppression of kidney cancer and suggests potentially significant new roles for coregulators in renal cancer biology...
  48. pmc Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells
    Yihui Fan
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX, USA Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
    J Pathol 232:75-86. 2014
    ....
  49. pmc An epigenomic approach to therapy for tamoxifen-resistant breast cancer
    Qin Feng
    Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Cell Res 24:809-19. 2014
    ..Taken together, we provide evidence that the epigenomic proteins BRD3/4 and WHSC1 are essential regulators of estrogen receptor signaling and are novel therapeutic targets for treatment of Tam-R breast cancer. ..
  50. pmc Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer
    Xiaoyong Fu
    Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Breast 22:S12-8. 2013
    ..Potential therapeutic approaches based on these findings are also discussed. ..
  51. pmc Die and let live: harnessing BikDD to combat breast cancer stem cells
    Mario Giuliano
    Lester and Sue Smith Breast Center at Baylor College of Medicine, Houston, TX 77030, USA
    Breast Cancer Res 14:310. 2012
    ..This novel and promising therapy warrants further translation to the clinic...
  52. pmc Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis
    Michael J Toneff
    Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    Neoplasia 12:718-26. 2010
    ....
  53. doi request reprint Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells
    Laura B Carpin
    Department of Bioengineering, Rice University, 6100 Main St, MS 142, Houston, TX 77005, USA
    Breast Cancer Res Treat 125:27-34. 2011
    ..This study suggests potential for applying gold nanoshell-mediated therapy to trastuzumab-resistant breast cancers in vivo...
  54. ncbi request reprint Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth
    Yongmin Liu
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston Texas, TX 77030, USA
    Oncogene 21:7680-9. 2002
    ..These results suggest that novel agents specifically targeting AP-1 or its activating kinases could be promising agents for the treatment of breast cancer...
  55. ncbi request reprint The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm
    Sara Lopez-Tarruella
    The Breast Center, Duncan Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 13:6921-5. 2007
  56. pmc Compartmentalized Ras proteins transform NIH 3T3 cells with different efficiencies
    Chiang Min Cheng
    Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, 1 Baylor Plaza, Baylor College of Medicine, Houston, TX 77030, USA
    Mol Cell Biol 31:983-97. 2011
    ....
  57. ncbi request reprint New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation
    Adrian V Lee
    Department of Medicine, Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 9:516S-23S. 2003
    ..This review will highlight how recent studies using these STIs have elucidated novel mechanisms of STI action that may be used in the development of new therapeutic strategies for the treatment of cancer...
  58. pmc HER2: biology, detection, and clinical implications
    Carolina Gutierrez
    Baylor College of Medicine, Department of Pathology, One Baylor Plaza, Houston, TX 77030, USA
    Arch Pathol Lab Med 135:55-62. 2011
    ..When shown to be overexpressed or amplified by appropriate methods, HER2 is a valuable treatment target...
  59. ncbi request reprint Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer
    Thushangi N Pathiraja
    Graduate program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX 77030, USA
    Sci Transl Med 6:229ra41. 2014
    ..Therapies aimed at inhibiting AI-induced histone and DNA methylation may be beneficial in blocking or delaying AI resistance. ..
  60. pmc The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo
    Kristen L Meerbrey
    Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 108:3665-70. 2011
    ..This feature allows isolation of cell populations that exhibit a potent, inducible target knockdown in vitro and in vivo that can be used in human xenotransplantation models to examine cancer drug targets...
  61. ncbi request reprint Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement
    Steven E Come
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 10:327S-330S. 2004
  62. ncbi request reprint Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells
    Sanaa M Nabha
    Department of Pathology, Wayne State University School of Medicine, 540 E Canfield, Detroit, MI 48201, USA
    Oncogene 24:3166-76. 2005
    ..05). Taken together, these data suggest that PKC-delta plays a major role in antiestrogen resistance in breast tumor cells and thus provides a new target for treatment...
  63. ncbi request reprint Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer
    Suleiman Massarweh
    Department of Internal Medicine and Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
    Cancer Res 66:8266-73. 2006
    ..Combining endocrine therapy with EGFR/HER-2/neu inhibitors should be tested in clinical breast cancer, but a more complete blockade of EGFR/HER-2/neu may be optimal...
  64. ncbi request reprint Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action
    William R Harrington
    University of Illinois, Department of Molecular and Integrative Physiology, 524 Burrill Hall, 407 South Goodwin Avenue, Urbana, Illinois 61801 3704, USA
    Mol Endocrinol 20:491-502. 2006
    ....
  65. doi request reprint Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function
    Suleiman Massarweh
    Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
    Cancer Res 68:826-33. 2008
    ..This study provides a rationale to combine HER inhibitors with tamoxifen in clinical studies, even in tumors that do not initially overexpress EGFR/HER2...